Customer Success Manager

MedScout raises $10M and launches AI agents for MedTech commercial teams. Posted On February 25, 2026 Backed by Fulcrum Equity Partners, MedScout has grown enterprise revenue by 3x since its Series A as MedTech companies adopt AI agents to turn commercial strategy into field execution AUSTIN, TX - Feb 25 MedScout, the commercial engine for MedTech, announced a $10M growth round led by Fulcrum Equity Partners, with participation from existing investors Live Oak Venture Partners and Stage 2 Capital. The round, which more than doubled the company's valuation from its Series A, will fuel continued investment in MedScout's AI capabilities and support growing demand from enterprise customers. "MedScout is tackling one of the most pressing challenges in MedTech: turning company strategy into revenue performance," said Philip Lewis, Partner at Fulcrum Equity Partners. "What they've built combines commercial expertise and AI to solve that problem in a highly actionable way that's unique to each customer. This is the future of how companies put AI to work, and it's why we're doubling down on our investment in MedScout." Alongside the funding, MedScout is launching Strategies, AI agents that analyze market and account-level referral networks, procedure volumes, payer dynamics, and more to deliver prioritized, ready-to-work territory plans to reps. Discover more The Bhagavad Gita Shrimad Bhagavad Gita "MedTech companies spend months developing commercial strategies that don't make it to the field as intended," said Skylar Talley, Co-founder and CEO of MedScout. "MedScout bridges that gap by translating commercial priorities into clear, territory-specific actions. Sales reps know which providers to prioritize and how to build and expand those relationships." MedTech commercial teams face a core disconnect: strategy is set at the top, but the tools reps use in the field don't reflect it. Instead, reps rely on Google, stale spreadsheets, or data platforms that lack the context to tell them what really matters. Each Strategy is an AI agent built around a company's specific commercial context, how it wins in the market, and its definition of a best-fit target. Drawing on industry expertise and field-tested patterns from working with hundreds of MedTech commercial teams, each agent can pinpoint the accounts and physicians most likely to convert. MedScout made Strategies available to customers in late 2025. "In January, our customers deployed 81% more unique AI agents than the month before - evidence that sales teams are seeing value quickly and building on early success," said Talley. MedScout's growth reflects the urgency of the problem it solves. Enterprise MedTech organizations are increasingly relying on MedScout to keep their large and distributed sales forces focused on the right accounts and opportunities. Enterprise revenue has grown 3x since its Series A in July 2024, and monthly active reps are up 135% month over month as sales teams expand their use of Strategies. "Everything we do is in service of better patient outcomes, and that starts with getting our innovations into the hands of the right clinicians," said Meraj Khan, Chief Marketing Officer, Surgical Innovations at GE Healthcare. "MedScout has been a strategic partner in helping our field teams identify, prioritize, and connect with the facilities and providers where our technologies can have the greatest impact. The result is stronger commercial performance and more patients benefiting from precision care. We're proud to work with MedScout and excited for this next phase of our partnership." MedScout customers deploy Strategies aligned to their specific growth priorities and market positioning, such as: * A surgical robotics company pinpoints orthopedic surgeons who perform high volumes of traditional total knee replacements, have a Medicare-heavy patient mix (60%+), and haven't adopted robotic-assisted procedures. Reps get a clear list of high-fit targets where the clinical case for adoption is already established. * A diagnostic imaging company identifies primary care physicians within a 25-mile radius of a priority account who see patients with pulmonary nodules but refer lung biopsies to competing practices. Reps receive a prioritized list of physicians whose referral patterns offer the greatest opportunity to expand biopsy volume at the target facility. * A cardiology device company identifies hospitals that performed 30% fewer TAVR procedures year over year while maintaining 250+ annual cardiac catheterization cases. Reps get a ranked list of high-capacity programs losing structural heart volume - a clear signal to re-evaluate technology partnerships. Each site has a tailored ROI story that quantifies revenue at risk and frames a path to recapture volume. MedScout is actively deploying Strategies within commercial teams across MedTech.

MedScout raises $10M and launches AI agents for MedTech commercial teams. Backed by Fulcrum Equity Partners, MedScout has grown enterprise revenue by 3x since its Series A as MedTech companies adopt AI agents to turn commercial strategy into field execution AUSTIN, TX - Feb 25 MedScout, the commercial engine for MedTech, announced a $10M growth round led by Fulcrum Equity Partners, with participation from existing investors Live Oak Venture Partners and Stage 2 Capital. The round, which more than doubled the company's valuation from its Series A, will fuel continued investment in MedScout's AI capabilities and support growing demand from enterprise customers. "MedScout is tackling one of the most pressing challenges in MedTech: turning company strategy into revenue performance," said Philip Lewis, Partner at Fulcrum Equity Partners. "What they've built combines commercial expertise and AI to solve that problem in a highly actionable way that's unique to each customer. This is the future of how companies put AI to work, and it's why we're doubling down on our investment in MedScout." Alongside the funding, MedScout is launching Strategies, AI agents that analyze market and account-level referral networks, procedure volumes, payer dynamics, and more to deliver prioritized, ready-to-work territory plans to reps. "MedTech companies spend months developing commercial strategies that don't make it to the field as intended," said Skylar Talley, Co-founder and CEO of MedScout. "MedScout bridges that gap by translating commercial priorities into clear, territory-specific actions. Sales reps know which providers to prioritize and how to build and expand those relationships." MedTech commercial teams face a core disconnect: strategy is set at the top, but the tools reps use in the field don't reflect it. Instead, reps rely on Google, stale spreadsheets, or data platforms that lack the context to tell them what really matters. Each Strategy is an AI agent built around a company's specific commercial context, how it wins in the market, and its definition of a best-fit target. Drawing on industry expertise and field-tested patterns from working with hundreds of MedTech commercial teams, each agent can pinpoint the accounts and physicians most likely to convert. MedScout made Strategies available to customers in late 2025. "In January, our customers deployed 81% more unique AI agents than the month before - evidence that sales teams are seeing value quickly and building on early success," said Talley. MedScout's growth reflects the urgency of the problem it solves. Enterprise MedTech organizations are increasingly relying on MedScout to keep their large and distributed sales forces focused on the right accounts and opportunities. Enterprise revenue has grown 3x since its Series A in July 2024, and monthly active reps are up 135% month over month as sales teams expand their use of Strategies. "Everything we do is in service of better patient outcomes, and that starts with getting our innovations into the hands of the right clinicians," said Meraj Khan, Chief Marketing Officer, Surgical Innovations at GE Healthcare. "MedScout has been a strategic partner in helping our field teams identify, prioritize, and connect with the facilities and providers where our technologies can have the greatest impact. The result is stronger commercial performance and more patients benefiting from precision care. We're proud to work with MedScout and excited for this next phase of our partnership." MedScout customers deploy Strategies aligned to their specific growth priorities and market positioning, such as: * A surgical robotics company pinpoints orthopedic surgeons who perform high volumes of traditional total knee replacements, have a Medicare-heavy patient mix (60%+), and haven't adopted robotic-assisted procedures. Reps get a clear list of high-fit targets where the clinical case for adoption is already established. * A diagnostic imaging company identifies primary care physicians within a 25-mile radius of a priority account who see patients with pulmonary nodules but refer lung biopsies to competing practices. Reps receive a prioritized list of physicians whose referral patterns offer the greatest opportunity to expand biopsy volume at the target facility. * A cardiology device company identifies hospitals that performed 30% fewer TAVR procedures year over year while maintaining 250+ annual cardiac catheterization cases. Reps get a ranked list of high-capacity programs losing structural heart volume - a clear signal to re-evaluate technology partnerships. Each site has a tailored ROI story that quantifies revenue at risk and frames a path to recapture volume. MedScout is actively deploying Strategies within commercial teams across MedTech.

MedScout secures $10M growth investment and unveils AI agents for commercial teams. Published February 24, 2026 MedScout Co-Founder and CEO: Skylar Talley MedScout, the Austin-based revenue acceleration platform for medical technology companies, has raised a $10 million growth round led by Fulcrum Equity Partners, with follow-on support from Live Oak Venture Partners and Stage 2 Capital. Financial terms beyond the raise amount were not disclosed. The funding follows the company's $15 million Series A in 2024 and coincides with the launch of Strategies, a new suite of AI-powered agents designed to translate commercial strategy into clear, data-backed field execution for MedTech sales teams. Bringing data and execution closer together. MedScout positions itself as a commercial intelligence layer purpose-built for medical device and diagnostics companies. The platform aggregates healthcare claims data and other market signals to give sales and marketing teams a unified view of providers, referral networks, procedure volumes, and payer dynamics. In practice, this means commercial leaders can move beyond static reports or disconnected spreadsheets. Instead of simply visualizing data, the system is structured to generate prioritized actions that reflect each company's go-to-market strategy and competitive positioning. What the new AI agents do. The newly introduced Strategies function as AI agents configured around a company's specific definition of a best-fit account. They analyze referral relationships, procedure trends, geographic patterns, and adoption signals to create ranked territory plans for field reps. For example, a surgical robotics company can identify orthopedic surgeons performing high volumes of traditional knee replacements who have yet to adopt robotic-assisted approaches. A cardiology device company can pinpoint hospitals with declining structural heart volumes despite maintaining strong catheterization capacity - highlighting potential opportunities to re-evaluate technology partnerships. Rather than asking reps to interpret raw data, the agents deliver ready-to-work target lists and contextual insights that align daily activities with broader commercial objectives. Closing the strategy-to-field gap. A persistent challenge in MedTech has been the disconnect between executive-level strategy and frontline execution. Companies may spend months refining growth priorities, yet field teams often rely on generic search tools, outdated spreadsheets, or CRM data lacking real-world clinical context. MedScout's approach is built around narrowing that gap. By embedding AI-driven insights directly into CRM workflows and territory planning processes, the platform aims to make strategic intent tangible at the rep level. The company reports that enterprise revenue has grown threefold since its Series A in mid-2024. At the same time, monthly active rep usage has climbed significantly, suggesting that adoption is expanding within existing customer organizations. The broader implications for MedTech commercial operations. The rollout of AI agents in MedTech sales points to a structural shift in how commercial teams operate. Instead of relying on static territory plans and rep intuition, organizations could move toward continuously updated, data-driven execution models that adapt as referral patterns, procedure volumes, and competitive dynamics change. This evolution may also reshape territory design, resource allocation, and performance measurement. Planning cycles that once operated quarterly or annually could become more fluid, with AI surfacing opportunities in near real time. For new reps, embedded intelligence may shorten ramp times by contextualizing complex provider networks and market dynamics from day one. More broadly, AI's expansion into commercial infrastructure signals a maturing phase for the technology in healthcare. Beyond clinical applications, artificial intelligence is increasingly being woven into operational decision-making - potentially becoming foundational to how MedTech companies scale growth and compete in data-intensive markets. Antoine is a visionary leader and founding partner of Unite.AI, driven by an unwavering passion for shaping and promoting the future of AI and robotics. A serial entrepreneur, he believes that AI will be as disruptive to society as electricity, and is often caught raving about the potential of disruptive technologies and AGI. As a futurist, he is dedicated to exploring how these innovations will shape our world. In addition, he is the founder of Securities.io, a platform focused on investing in cutting-edge technologies that are redefining the future and reshaping entire sectors.